Trypsin is an enzyme produced by the pancreas that helps to digest proteins. Trypsin breaks down proteins in the small intestine. It is also called as proteolytic enzyme or proteinase. Trypsin is formed by the pancreas in an inactive form trypsinogen and is converted to the active form trypsin when it enters the small intestine. Trypsin along with other two proteinases pepsin and chymotrypsin breaks down the dietary protein into amino acids and peptides. These amino acids are important for hormone production, muscle growth, and bodily functions.
The global trypsin market is estimated to be valued at US$ 42.95 million in 2021 and is expected to exhibit a CAGR of 4.3% during the forecast period (2021-2028).
Figure 1.Global Trypsin Market Share (%) in Terms of Value, by Source, 2021
Increasing product launches is expected to drive the market growth during the forecast period.
The increasing product launches is expected to drive growth of the global trypsin market over the forecast period. For instance, in May 2017, Merck KGaA announced the launch of advanced proteomics grade SOLu-Trypsin. Moreover, SOLu-Trypsin is a stable enzyme for mass spectrometry.
|Base Year:||2020||Market Size in 2021:||US$ 42.95 Mn|
|Historical Data for:||2017 to 2020||Forecast Period:||2021 to 2028|
|Forecast Period 2021 to 2028 CAGR:||4.3%||2028 Value Projection:||US$ 57.71 Mn|
Promega Corporation, Merck KgaA, Geno Technology Inc., USA., Thermo Fisher Scientific Inc., SignalChem Biotech Inc., Takara Bio Inc., Creative Enzymes, ProteoChem, Waters Corporation, Bioseutica, Bovogen Biologicals Pty Ltd., and BBI Solutions
|Restraints & Challenges:||
Figure 2. Global Trypsin Market Share (%), by Product Type, 2021
The use of trypsin to treat common cold is expected to drive the market growth during the forecast period.
Manufacturers are engaged in the development of trypsin (ColdZyme) in oral spray to protect against COVID-19 and common colds. The use of trypsin to treat common cold diseases will provide various market players the opportunity to expand their product portfolio. For instance, according to an article published in International Environmental Research and Public Health, in May 2021, ColdZyme, a medical device mouth spray, developed by Enzymatics, a leading producer of reagents, kits, and assays, stated that it inactivates the human coronavirus and SARS-CoV-2, as well as rhinovirus, adenovirus, influenza, and respiratory syncytial virus (RSV).
Global Trypsin Market – Impact of Coronavirus (COVID-19) Pandemic
Since the COVID-19 virus outbreak in December 2019, the disease has spread to over 100 countries across the globe and the World Health Organization has declared it a public health emergency on January 30, 2020.
COVID-19 can affect the economy in three main ways; by directly affecting production and demand, by creating disruptions in distribution channels, and through its financial impact on firms and financial markets. Due to nationwide lockdowns, several countries such as China, India, Saudi Arabia, UAE, Egypt, and others are facing problems with regards to transportation of drugs from one place to another.
Furthermore, players operating in the global trypsin market are facing major challenges on various fronts due to the COVID-19 pandemic. The major challenges include supply of raw materials required for manufacturing and drug formulations due to irregularities in transportation. Moreover, distributors are experiencing irregular demand for products from the retailers due to an increase in the number of patients suffering from COVID-19 and other life threatening disorders.
Global Trypsin Market: Restraint
The major factors that are expected to hinder growth of the global trypsin market include trypsin’s autolysis property and incomplete digestion of trypsin. As trypsin is a protein, it may undergo autolysis or auto digestion, a process of destruction of cells by its own enzymatic action. This is expected to hinder growth of the global trypsin market over the forecast period. Moreover, while using trypsin, there is no assurance that all the protein will be completely digested. Around 10% to 30% of undigested trypsin sites are left.
Major players operating in the global trypsin market include Promega Corporation, Merck KgaA, Geno Technology Inc., USA, Thermo Fisher Scientific Inc., SignalChem Biotech Inc., Takara Bio Inc., Creative Enzymes, ProteoChem, Waters Corporation, Bioseutica, Bovogen Biologicals Pty Ltd., and BBI Solutions.
Trypsin is a proteolytic enzyme that aids in digestion. Inactive trysinogen formed by the pancreas gets converted into active trypsin in the small intestine. Trypsinogen, along with other proetinases like pepsin and chymotrypsin, breaks down protein from food into amino acids. Amino acids carry out various functions such as repairing tissues, producing hormones, potentiating muscle growth, and others. When enough trypsin is not produced by the body, it leads to a condition called malabsorption. Moreover, malabsorption may also occur due to a number of conditions such as cystic fibrosis, pancreatitis, and others. Trypsin is given to patients who lack the digestive enzymes required.
The increasing adoption of inorganic strategies such as collaborations and agreements by the key players is expected to drive the global trypsin market over the forecast period. For instance, in September 2021, Thermo Fisher Scientific, a U.S.-based supplier of scientific instrumentation, reagents and consumables, and software services, and AstraZeneca, a multinational pharmaceutical and biotechnology company, announced to collaborate to develop next-generation sequencing (NGS)-based companion diagnostics (CDx). This collaboration was to support AstraZeneca's growing portfolio of targeted therapies. The companies will work together on a multiyear, global agreement.
Key features of the study:
“*” marked represents similar segmentation in other categories in the respective section.